Clinical Trial Update: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Orforglipron for stress urinary incontinence in women who are overweight or obese; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stress Urinary Incontinence
• Urinary Incontinence

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Urinary Incontinence,Stress | Phase 3 | Status: RECRUITING